Evaluation of effects of Squill Oxymel on non-alcoholic fatty liver.

Evaluation of the effectiveness of traditional medicine product squill oxymel on the laboratory indices of blood lipids, liver enzymes and sonographic findings in non-alcoholic fatty liver patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250608066109N1

Enrollment

Registered

2025-08-14

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Squill Oxymel syrup (manufactured by Tooba Company) will be consumed daily at 20 cc (containing 0.25 mg of Squill per 5 cc) as 10 cc in the morning on an empty stom

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with fatty liver (grade 1-3) Body mass index above 25 ( BMI > 25 )

Exclusion criteria

Exclusion criteria: Having liver fibrosis and cirrhosis Cardiovascular disease and high blood pressure Kidney diseases Diabetes disease Stomach ulcers and history of digestive diseases Blood coagulation problems and use of anticoagulant medications Concomitant use of other herbal medicines for fatty liver by the patient Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Alkaline Phosphatase. Timepoint: Measurement of Alkaline Phosphatase in the patients' blood at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Fatty liver status (grading). Timepoint: Assessment of fatty liver status (grading) at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Liver sonography.;Triglycerides. Timepoint: Measurement of patients' triglycerides at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;LDL (Low-Density Lipoprotein). Timepoint: Measurement of LDL cholesterol in patients at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Serum Glutamic-Oxaloacetic Transaminase. Timepoint: Measurement of Serum Glutamic Oxaloacetic Transaminase in patients at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Serum Glutamic-Pyruvic Transamonase. Timepoint: Measurement of Serum Glutamic Pyruvic Transaminase in patients at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Total Cholesterol. Timepoint: Measurement of total blood cholesterol in patients at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.	—

Measure

Time frame

Alkaline Phosphatase. Timepoint: Measurement of Alkaline Phosphatase in the patients' blood at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Fatty liver status (grading). Timepoint: Assessment of fatty liver status (grading) at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Liver sonography.;Triglycerides. Timepoint: Measurement of patients' triglycerides at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;LDL (Low-Density Lipoprotein). Timepoint: Measurement of LDL cholesterol in patients at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Serum Glutamic-Oxaloacetic Transaminase. Timepoint: Measurement of Serum Glutamic Oxaloacetic Transaminase in patients at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Serum Glutamic-Pyruvic Transamonase. Timepoint: Measurement of Serum Glutamic Pyruvic Transaminase in patients at the beginning of the study (before intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.;Total Cholesterol. Timepoint: Measurement of total blood cholesterol in patients at the beginning of the study (before the intervention), 6 weeks later, and 12 weeks after the start of the intervention. Method of measurement: Photometric method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhad Banagozar Mohammadi

Tabriz University of Medical Sciences

sadiahad@gmail.com009834133379528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026